FdaApplication
BLA 125359
Identifiers
- fda_app_no: BLA125359
Properties
| Property | Value |
|---|---|
| applicant_name | Jazz Pharmaceuticals, Inc. |
| application_type | BLA |
| approval_date | 2011-11-18 |
Revenue by product
ERWINAZE
| Period | Revenue |
|---|---|
| FY 2023 | $0.0M |
| FY 2022 | $0.0M |
| FY 2021 | $69.4M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ERWINAZE | — | 10,000INTERNATIONAL UNITS | For Injection |
1 product